Search bioRxiv⌕ Search

Biology subjects

Shearer, S. M.

Publications and source records attributed to Shearer, S. M..

2 recordsLinked to original sources

Pulmonary fibroblast activation during Aspergillus fumigatus infection enhances lung defense via immunomodulation and tissue remodeling

Aspergillus fumigatus is the etiologic agent of invasive aspergillosis, a life- threatening fungal pneumonia that is initiated by the inhalation of conidia (spores) into the lung. If the conidia are not cleared, they secrete large quantities of hydrolytic enzymes and toxins as they grow, resulting in extensive damage to pulmonary tissue. Stromal fibroblasts are central responders to tissue damage in many organs, but their functional response to pulmonary injury caused by A. fumigatus has not been explored. In this study, we employed cell lineage tracing, targeted cell ablation, and single-cell RNA sequencing to monitor the dynamics of fibroblast behavior upon exposure to A. fumigatus in both immunocompetent and immunosuppressed hosts. The results demonstrate that a subset of pulmonary fibroblasts becomes activated in an immunocompetent host in response to a challenge with A. fumigatus conidia, acquiring a gene expression program reflecting the acquisition of new immunomodulatory properties as well as enhanced extracellular matrix (ECM)-secreting ability. Remarkably, through targeted ablation of fibroblasts that express the profibrotic activation marker periostin, we demonstrate that the progression of an invasive A. fumigatus infection in an immunosuppressed host is accelerated by the absence of periostin lineage cells and is accompanied by severe alveolar hemorrhage and angioinvasion. These findings uncover a novel protective role for fibroblasts in limiting the severity of A. fumigatus-induced pulmonary injury and emphasize the importance of the pulmonary stroma in host defense against this invasive fungal infection.

cell biology↗

Attenuation of Atherosclerosis with PAR4 Deficiency: Differential Platelet Outcomes in apoE-/- vs. Ldlr-/- Mice

ObjectiveCardiovascular disease (CVD) is a significant burden globally and, despite current therapeutics, remains the leading cause of death. Platelet inhibitors are of interest in CVD treatment to reduce thrombus formation post-plaque rupture as well their contribution to inflammation throughout the progression of atherosclerosis. Protease activated receptor 4 (PAR4) is a receptor highly expressed by platelets, strongly activated by thrombin, and plays a vital role in platelet activation and aggregation. However, the role of PAR4 Approach and ResultsMice on a low-density lipoprotein receptor-deficient (Ldlr-/-) background were bred with Par4 deficient (Par4-/-) mice to create Ldlr-/-/Par4+/+ and Ldlr-/-/Par4-/- cousin lines. Mice were fed high fat (42%) and cholesterol (0.2%) Western diet for 12 weeks for all studies. Bone marrow transplant (BMT) studies were conducted by irradiating Ldlr-/-/Par4+/+ and Ldlr-/- /Par4-/- mice with 550 rads (2x, 4 hours apart) and then repopulated with Par4+/+ or Par4-/- bone marrow. To determine if the effects of thrombin were mediated solely by PAR4, the thrombin inhibitor dabigatran was added to the Western diet. Ldlr-/-/Par4-/- given dabigatran did not further decrease their atherosclerotic burden. Differences between apolipoprotein E deficient (apoE-/-) and Ldlr-/- platelets were assessed for changes in reactivity. We observed higher PAR4 abundance in arteries with atherosclerosis in human and mice versus healthy controls. PAR4 deficiency attenuated atherosclerosis in the aortic sinus and root versus proficient controls. BMT studies demonstrated this effect was due to hematopoietic cells, most likely platelets. PAR4 appeared to be acting independent of PAR1, as there werer no changes with addition of dabigatran to PAR4 deficient mice. apoE-/- platelets are hyperreactive compared to Ldlr-/- platelets. ConclusionsHematopoietic-derived PAR4, most likely platelets, plays a vital role in the development and progression of atherosclerosis. Specific targeting of PAR4 may be a potential therapeutic target for CVD. HighlightsO_LIDeficiency of protease-activated receptor 4 attenuates the development of diet-induced atherosclerosis in a Ldlr-/- mouse model. C_LIO_LIPAR4 deficiency in hematopoietic cells is atheroprotective. C_LIO_LIPAR4 deficiency accounts for the majority of thrombin-induced atherosclerosis in a Ldlr-/- mouse model. C_LIO_LIThe examination of platelet-specific proteins and platelet activation should be carefully considered before using the apoE-/- or Ldlr-/- mouse models of atherosclerosis. C_LI

pathology↗